LFR
EIGR

Lehman Financial Resources’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Lehman Financial Resources’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1
Closed – – 378
2015
Q3 		$0 Hold
1
– – ﹤0.01% 493
2015
Q2 		$0 Buy
+1
New +$2.77K ﹤0.01% 448

Other funds holding EIGR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lehman Financial Resources's EIGR Position: Q4 2015 in Review

Lehman Financial Resources sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2015, closing a stake of 1 share.

Lehman Financial Resources first reported a position in EIGR in Q2 2015 and held it in 2 quarters. The position peaked at $0 in Q3 2015. 41 funds tracked by Wall St. Rank hold EIGR as of Q4 2015.

  • Lehman Financial Resources reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Lehman Financial Resources sold 1 Eiger BioPharmaceuticals, Inc. share in Q4 2015.
  • Lehman Financial Resources first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2015 and held it in 2 quarters.
  • Lehman Financial Resources's Eiger BioPharmaceuticals, Inc. position peaked at $0 in Q3 2015.
  • 41 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2015.

Based on Lehman Financial Resources's 13F filing for Q4 2015, filed 17 Feb 2016.